

Different Stages of Platelet Adhesion to the Site of Vascular Injury

Hosseini E,¹ Ghasemzadeh M,^{1, 2*}

1- Blood Transfusion Research Centre, Iranian Blood Transfusion Organization, Tehran, Iran

2- Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

*Corresponding Author: Ghasemzadeh M, Email: mehran1476@yahoo.com

Submitted: 29-06-2011, Accepted: 20-03-2012

Abstract

Platelet activation and adhesion to the site of vascular injury is a dynamic process comprising reversible and irreversible phases. Platelet adhesion typically occurs in a multi-step process similar to the selectin/integrin-mediated adhesion of neutrophils. This phenomenon is highly regulated and influenced by the cross-talk between platelets and injured endothelium. This cross-talk involves a variety of mediators including adhesion molecules and receptors, agonists, chemokines, shed proteins and various proinflammatory lipids.

This review briefly discusses the main adhesion molecules and receptors involved in both reversible and irreversible phases of platelet adhesion to the site of vascular injury, leading to a better characterization of the multistep mechanisms of thrombus formation.

Keywords: Platelet, adhesion molecules, procoagulant activity, thrombosis

Introduction

Platelets are small anucleate cells that are derived from cytoplasmic fragments of bone marrow megakaryocytes. Resting platelets have a flat, featureless discoid morphology that is ideally suited for their circulation through the microvasculature^{1,2}. The mean size of platelets varies amongst individuals, ranging from approximately 1.5 to 3.0 μm in diameter and appears to follow a log normal distribution³. The platelet plasma membrane is composed of a bilayer of phospholipids consisting of cholesterol, glycolipids and glycoproteins including functional receptors and ligands⁴. The negatively charged phospholipids are almost exclusively present in the inner leaflet of resting platelets⁵, however following platelet activation by potent agonists, these aminophospholipids are exteriorized and are able to accelerate several steps in the coagulation reaction, ultimately generating thrombin. Thus the presence of these lipids in the inner leaflet of resting platelets is considered a control mechanism to prevent inappropriate coagulation activation⁶⁻⁸.

Platelets typically circulate in the bloodstream for 7-10 days and their principal function is to survey the inner lining of blood vessels to detect

breaches in the vasculature. They rapidly adhere to sites of blood vessel injury, aggregate with one another and facilitate the generation of thrombin. These events are critical for the normal haemostatic process. Primary platelet adhesion and aggregation leads to the formation of a platelet plug (termed the primary haemostatic plug), while subsequent thrombin generation and the conversion of soluble fibrinogen to fibrin acts to consolidate the primary haemostatic plug (termed secondary haemostasis) and stop bleeding. Platelet activation and adhesion to the site of vascular injury typically occur in a multi-step process similar to the selectin/integrin-mediated adhesion of neutrophils. This is a dynamic process comprising reversible and irreversible phases which is tightly regulated to avoid excessive platelet accumulation at the injury site and vascular obstruction, the principal pathological process causing heart attacks and ischaemic stroke. This review discusses aforementioned process, with respect to its distinct multi-step stages, to afford a clear picture into the complex molecular mechanisms of primary events in thrombus formation.

Platelet adhesion

Macromolecular adhesion proteins

von Willebrand factor (vWf)

vWf is an adhesive multimeric glycoprotein which contains binding sites for numerous proteins, including platelet membrane glycoproteins and constituents of the subendothelial matrix. vWf is synthesized in endothelial cells⁹ and in megakaryocytes^{10, 11}. In endothelial cells, vWf is packaged into secretory vesicles known as Weibel-Palade bodies where its release is tightly regulated. In addition, the protein is constitutively secreted from the basal side of the endothelial cell where it becomes part of the subendothelial matrix¹². In megakaryocytes, vWf is packaged into α -granules where it is released upon platelet stimulation^{13, 14}. The protein contains several important domains that enable it to interact with other subendothelial proteins and platelet receptors. The A1 domain is possibly the most important functional part of the molecule since it contains binding sites for GPIb α , collagen, sulphatides and heparin^{15, 16}. The carboxyl-terminal end of individual vWf subunits (C1 domain) contains an arginine-glycine-aspartic acid (RGD) sequence that is important for its interaction with activated integrins, in particular platelet integrin α IIb β 3¹⁷⁻¹⁹.

Fibrinogen

Fibrinogen circulates as a dimer made up of three polypeptide chains A α , B β and γ which are disulphide linked (20). Similar to vWf, fibrinogen is found in two pools, in plasma and platelet α -granules. However unlike vWf, megakaryocytes do not appear to synthesize fibrinogen; rather it is taken up from plasma and concentrated in the α -granules by a process that involves the integrin α IIb β 3 receptor²¹. The dodecapeptide sequence (HHLGGAKQAGDV) on the carboxyl-terminal end of the fibrinogen γ chain is the most important binding site for integrin α IIb β 3²²⁻²⁴. Other α IIb β 3 binding sites that have been identified on the fibrinogen molecule include two RGD sequences on the A α chain of each monomer. This is a recognized motif common amongst adhesive proteins important for binding to integrins. In soluble fibrinogen, the RGD sequences lie within the triple helical coiled domain without direct exposure to integrin α IIb β 3. However, when fibrinogen is immobilized to a surface, exposure of at least one of these sequences

allows it to bind the integrin α IIb β 3 in its inactive conformation²⁵.

Collagen

Collagen is a major constituent of the vessel wall and provides a highly reactive surface for platelets, thereby promoting rapid thrombus formation²⁶. Adhesion of platelets to collagen under high shear conditions is dependent on collagen-bound vWf²⁷⁻²⁹. The interaction between collagen-bound vWf and the platelet receptor GPIb/V/IX is critical to initiate platelet adhesion under rapid blood flow conditions, slowing platelet movement at the vessel wall to enable receptor-ligand interactions with slower-binding kinetics, such as the collagen-GPVI or collagen-integrin α 2 β 1, to promote platelet arrest³⁰.

At least 25 types of collagen have been identified³¹ of which types I, III, IV, V and VI are the most abundant in the vascular wall³². Collagen types I-IV are highly reactive for platelets³³ supporting adhesion and aggregate formation under low shear conditions. Other collagens vary considerably in their ability to support platelet adhesion and activation, and their pathophysiological importance in mediating these events is unclear^{33, 34}.

Adhesion receptors

The GPIb-V-IX complex

This receptor complex belongs to the leucine-rich glycoprotein family of adhesion receptors and serves as the primary receptor for vWf^{35, 36}. Each receptor complex is comprised of four separate glycoproteins arranged in a specific order. GPIb is a heterodimer of a larger α chain (GPIb α) and a smaller disulfide linked β chain (GPIb β) which forms a non-covalent complex with GPIIX. Two GPIb/IX complexes are linked together by GPV forming the complete receptor³⁷. GPIb α is the largest and the most important part of the complex and contains the binding site for vWf³⁸. In arterioles where the shear rates are high, the initial capture of platelets on sub-endothelial collagen is mediated by collagen bound vWf interacting with GPIb-V-IX. On the other hand, on a developing thrombus additional platelets are recruited by the interaction of GPIb-V-IX on flowing platelets, with vWF bound to activated integrin α IIb β 3, on the surface of the thrombus^{30, 39-41}. The binding of vWF to GPIb-V-IX induces platelet signaling that results in the upregulation of integrin

α IIb β 3 affinity⁴²⁻⁴⁷. This enables the integrin to bind VWF and fibrinogen thereby enhancing platelet adhesion and thrombus formation.

Collagen receptors

Integrin α 2 β 1 was the first platelet collagen receptor to be identified⁴⁸⁻⁵¹. The binding of collagen to this receptor has not been reported to stimulate tyrosine kinase activity, which is required for collagen-induced platelet activation. It has been proposed that this receptor, by anchoring the platelet to collagen, facilitates the interaction between collagen and a second receptor (GPVI) leading to cell signaling and platelet activation⁵². This model, in which platelet adhesion and activation are distinct events, is supported by more recent studies⁵³⁻⁵⁶.

GPVI belongs to the immunoglobulin receptor superfamily^{57,58}, and is non-covalently associated with FcR γ -chain, which serves as the signal-transducing component of the receptor^{59,60}. Studies on GPVI knockout mice support the hypothesis that GPVI is the dominant collagen receptor inducing platelet activation⁶¹⁻⁶⁴.

Integrin $\alpha_{IIIb}\beta_3$

Integrins are heterodimeric glycoproteins consisting of an α subunit complexed to a β subunit through non-covalent binding. At least 8 different β subunits and more than 16 different α subunits have been identified. Integrins on human cells are categorized by the β subunit of the heterodimer (i.e., β 1 or β 2 integrin subfamilies)^{65,66}. They mediate cell adhesion to extracellular matrix proteins and to other cells, as well as transmitting signals from the extracellular environment. These are essential for cell motility, growth and differentiation, cell survival, and specialized functions such as degranulation and oxidant production in immune cells⁶⁷⁻⁷¹.

Platelets express several integrins on their surface and of these integrins, α IIb β 3 is functionally the most important and most extensively studied. Integrin α IIb β 3 is the most abundant of all the platelet surface protein receptors and its expression is restricted to platelets and megakaryocytes^{72,73}. It plays a critical role in platelet adhesion, aggregation and spreading and its physiological importance is highlighted by the observation that individuals with Glanzmann's Thrombasthenia, where the receptor

is either absent or defective, have significant bleeding problems^{74,75}. Platelets from these patients are unable to aggregate in response to multiple physiological stimuli. Like other integrins, α IIb β 3 can exist in multiple stages of activation and its ligand binding function is tightly regulated. Cell signaling converts the integrin from a low to a high affinity receptor which enables it to engage its ligands, including fibrinogen, vWf, vitronectin and fibronectin through an RGD recognition sequence present on all these proteins⁷⁶⁻⁷⁸.

Mechanism of platelet adhesion to reactive surfaces

Platelet tethering

Platelet adhesion typically occurs in a multi-step process similar to the selectin/integrin-mediated adhesion of neutrophils. GPIb-V-IX plays a critical role in capturing free-flowing platelets to the vessel wall, its rapid binding kinetics enables platelet tethering even under conditions of high shear through an interaction with subendothelial-bound vWf. However, the accompanying rapid dissociation rate means this interaction supports platelet translocation and is therefore unable to maintain the cell in a state of stationary adhesion³⁹. During translocation on vWf, platelets undergo rapid morphological changes characterized by transition from a flat disc to a sphere with multiple filopodial protrusions⁴⁷. This is a critical period during which one of two scenarios may occur: 1) the platelet may detach and return to the circulation, or 2) it becomes activated leading to irreversible adhesion and thrombus formation.

Stable adhesion

The vWf/GPIb-V-IX interaction slows platelet velocity in the rapidly flowing blood allowing other receptors with slower binding kinetics to bind their specific ligands. Meanwhile, platelet activation contributed by multiple adhesion receptors and soluble agonists induces intracellular signaling mechanisms leading to the conversion of integrin α IIb β 3 from a low affinity to high affinity state. This enables the integrins to bind ligand and mediate stationary adhesion. Stationary adhesion is also critically supported by the binding of collagen receptors (GPVI and α 2 β 1) to collagen in the subendothelium³³. Cell activation is further enhanced through production of TXA2 and soluble

agonists such as ADP, thrombin and adrenaline, which bind to their respective receptors on the platelet surface. The majority of these receptors are linked to heterotrimeric G-proteins that serve to initiate an efficient inside-out signaling pathway in platelets, causing further integrin $\alpha_{IIb}\beta_3$ activation with the resultant enhancement in platelet adhesion and aggregation⁷⁹.

In response to potent soluble agonists, the platelet α -granules release their contents which are either shuttled to the plasma membrane or secreted to the extracellular milieu. This process is important in facilitating the development of platelet aggregates ($\alpha_{IIb}\beta_3$ and fibrinogen), wound healing (platelet derived growth factor), thrombin formation (factor V) or platelet-leukocyte interaction (P-selectin and CD40L)^{80, 81}.

Integrin $\alpha_{IIb}\beta_3$ activation: linking platelet aggregation to thrombus formation

Activation of integrin $\alpha_{IIb}\beta_3$ is tightly regulated through a process termed inside-out signaling. Agonists, such as ADP and thrombin, which engage GPCRs, or adhesive proteins, such as collagen or vWF, which interact with GPVI or GPIb-IX-V respectively, initiate intracellular signaling events that influence integrin affinity by modifying the cytoplasmic tail of α_{IIb} and or β_3 . These modifications propagate to the extracellular domain of the receptor resulting in alteration in the conformation of the ligand binding site and imparting binding competency to the integrin (review by Shattil et al 1998). Structural and crystallographic studies have proposed that in a low- affinity state, the ligand binding site of integrin is cryptic and becomes exposed following




Figure 1: Transformation of platelets from a proadhesive, proaggregatory to procoagulant and proinflammatory state under physiological flow conditions. Platelets are initially captured from free flowing blood through the binding of GPIb/V/IX to immobilized vWf expressed at sites of vascular injury. This interaction slows down platelet movement and allows GPVI to engage the exposed collagen. These interactions then trigger the activation of the major integrin $\alpha_{IIb}\beta_3$ which facilitates platelet stationary adhesion, spreading and subsequent aggregation through binding to vWf and fibrinogen. Activated platelets release granule stored ADP which promotes further platelet activation and thrombus growth through its receptors P2Y1 and P2Y12. The sustained calcium elevation within activated platelets results in the surface exposure of phosphatidylserine (PS) and transforms platelets from a proaggregatory to procoagulant state. The exposed PS initiates the generation of thrombin which through binding to PARs reinforces platelet activation and thrombus growth. In concert with other platelet stimuli such as collagen, thrombin induces Sustained Calcium Induced Platelet (SCIP) morphology which is associated with the specific production of inflammatory lipids to promote procoagulant and proinflammatory function of platelets.

conformational changes in the $\beta 3$ cytoplasmic tail⁸²⁻⁸⁴. Based on current data, integrin activation at the cytoplasmic tail involves a clasping/unclasping mechanism which provides the driving force to trigger the conformational changes in the extracellular domain⁸⁵. It is also known that the cytoplasmic domains of the receptor are critical for affinity modulation, as mutations in certain positions of the cytoplasmic tail can result in defective or enhanced activation of the integrin⁸⁶⁻⁸⁹. Integrin affinity modulation induced by inside-out signaling is critical for receptor activation and for the engagement of soluble ligands. Cross-linking of the receptor followed by the binding of activated integrins to multimeric ligands (e.g. fibrinogen and vWF), induces outside-in signaling pathways which trigger the clustering of integrins within the plane of the plasma membrane. This process enhances substrate-binding avidity and signaling capacity⁹⁰, leading to irreversible phases of platelet activation. In this phase fully activated platelets covered by clustered integrins become strongly cross-linked together through the ligation with fibrinogen molecules, resulting to initial phase of thrombus formation^{91,92}.

Thrombus formation

The firm adhesion of platelets to the site of injury forms a monolayer which serves as a reactive site for further recruitment of free-flowing platelets. Platelet accumulation is dependent on platelet-bound vWf and fibrinogen which serves to cross-link adjacent platelets and promote stable platelet aggregation as^{91,92}. This process is essential for the formation of a primary haemostatic plug and also for the development of pathological thrombi at site of atherosclerotic plaque rupture. During thrombus development, the sustained calcium elevation within activated platelets results in the surface exposure of phosphatidylserine (PS) and transforms platelets from a proaggregatory to pro-coagulant state. The exposed PS initiates the generation of thrombin, which through binding to PARs, reinforces platelet activation and thrombus growth. In concert with other platelet stimuli such as collagen, thrombin induces Sustained Calcium Induced Platelet morphology (SCIP) which is associated with the specific production of inflammatory lipids to promote procoagulant and proinflammatory function of platelets⁹³. Figure.1

demonstrates different steps thrombus development including platelet tethering, adhesion, aggregation, thrombus formation and procoagulant activation.

Conclusion

Over last three decades, the molecular mechanisms underlying platelet activation and adhesion have been increasingly well defined, particularly with respect to the key factors involved in the multi-step mechanisms of thrombus development. These achievements have been obtained through continuing advances in in vitro and in vivo experimental systems, combined with the development of genetically manipulated mouse models. However, better understanding of precise mechanisms regulating these events and how such well preserved conditions lead to an uncontrolled pathophysiological status, still remain the main interest of scientists in their current and future investigations to control and diminish the risk of cardiovascular diseases.

Acknowledgements

We thank Professor Shaun Jackson, Professor Hatem Slaem and Dr. Simone Schoenwaelder from Australian Centre for Blood Diseases, Monash University for all guidance and assistances which they provided during the preparation of this review.

References

1. White, J. G., and J. M. Gerrard. 1982. Anatomy and organization of platelet. In Hemostasis and Thrombosis. Colman,RW.,Hirsh,J.,Marder,V.J.,and Salzman,E.W.(Eds).J.B. Lippincott,Philadelphia,p343.
2. White, J. G. 1981. Morphological studies of platelets and platelet reactions. Vox sanguinis 40 Suppl 1:8-17.
3. Holme, S., A. Heaton, A. Konchuba, and P. Hartman. 1988. Light scatter and total protein signal distribution of platelets by flow cytometry as parameters of size. The Journal of laboratory and clinical medicine 112:223-31.
4. White, J. G. 1993. Anatomy and structural organization of the platelet, in: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edited by Colman,R.W., Hirsh, J., Marder,V.J., Salzman,E.W., p 397. JB Lippincott, Philadelphia, .
5. Schick, P. K. 1990. (1982) Megakaryocyte and platelet lipids, in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, (Eds) Colman,R.W.,

1. Hirsh, J., Marder, V. J., Salzman, E. W., JB Lippincott, Philadelphia, p 574
6. Heemskerk, J. W., E. M. Bevers, and T. Lindhout. 2002. Platelet activation and blood coagulation. *Thrombosis and haemostasis* 88:186-93.
 7. Solum, N. O. 1999. Procoagulant expression in platelets and defects leading to clinical disorders. *Arteriosclerosis, thrombosis, and vascular biology* 19:2841-6.
 8. Sims, P. J., T. Wiedmer, C. T. Esmon, H. J. Weiss, and S. J. Shattil. 1989. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. *The Journal of biological chemistry* 264:17049-57.
 9. Jaffe, E. A., L. W. Hoyer, and R. L. Nachman. 1974. Synthesis of von Willebrand factor by cultured human endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America* 71:1906-9.
 10. Nachman, R., R. Levine, and E. A. Jaffe. 1977. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. *The Journal of clinical investigation* 60:914-21.
 11. Sporn, L. A., S. I. Chavin, V. J. Marder, and D. D. Wagner. 1985. Biosynthesis of von Willebrand protein by human megakaryocytes. *The Journal of clinical investigation* 76:1102-6.
 12. Ewenstein, B. M., M. J. Warhol, R. I. Handin, and J. S. Pober. 1987. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. *The Journal of cell biology* 104:1423-33.
 13. Wencel-Drake, J. D., E. F. Plow, T. S. Zimmerman, R. G. Painter, and M. H. Ginsberg. 1984. Immunofluorescent localization of adhesive glycoproteins in resting and thrombin-stimulated platelets. *The American journal of pathology* 115:156-64.
 14. Wencel-Drake, J. D., R. G. Painter, T. S. Zimmerman, and M. H. Ginsberg. 1985. Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin, and von Willebrand factor in frozen thin section. *Blood* 65:929-38.
 15. Roth, G. J., K. Titani, L. W. Hoyer, and M. J. Hickey. 1986. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. *Biochemistry* 25:8357-61.
 16. Christophe, O., B. Obert, D. Meyer, and J. P. Girma. 1991. The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. *Blood* 78:2310-17.
 17. Huang, J., R. Roth, J. E. Heuser, and J. E. Sadler. 2008. Integrin $\alpha_v\beta_3$ on human endothelial cells binds von Willebrand factor strings under fluid shear stress. *Blood*.
 18. Reininger, A. J. 2008. Function of von Willebrand factor in haemostasis and thrombosis. *Haemophilia* 14 Suppl 5:11-26.
 19. Nurden, A. T., and P. Nurden. 1993. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. *Bailliere's clinical haematology* 6:653-90.
 20. Doolittle, R. F., K. W. Watt, B. A. Cottrell, D. D. Strong, and M. Riley. 1979. The amino acid sequence of the alpha-chain of human fibrinogen. *Nature* 280:464-8.
 21. Harrison, P., B. Wilbourn, E. Cramer, R. Faint, I. J. Mackie, S. Bhattacharya, A. Lahiri, D. Tenza, S. J. Machin, and G. F. Savidge. 1992. The influence of therapeutic blocking of Gp IIb/IIIa on platelet alpha-granular fibrinogen. *British journal of haematology* 82:721-8.
 22. Hawiger, J., S. Timmons, M. Kloczewiak, D. D. Strong, and R. F. Doolittle. 1982. gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. *Proceedings of the National Academy of Sciences of the United States of America* 79:2068-71.
 23. Kloczewiak, M., S. Timmons, and J. Hawiger. 1983. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. *Thrombosis research* 29:249-55.
 24. Kloczewiak, M., S. Timmons, T. J. Lukas, and J. Hawiger. 1984. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. *Biochemistry* 23:1767-74.
 25. Ugarova, T. P., A. Z. Budzynski, S. J. Shattil, Z. M. Ruggeri, M. H. Ginsberg, and E. F. Plow. 1993. Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa. *The Journal of biological chemistry*

- 268:21080-7.
26. Savage, B., F. Almus-Jacobs, and Z. M. Ruggeri. 1998. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* 94:657-66.
 27. Denis, C., D. Baruch, C. M. Kielty, N. Ajzenberg, O. Christophe, and D. Meyer. 1993. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. *Arterioscler Thromb* 13:398-406.
 28. Hoylaerts, M. F., H. Yamamoto, K. Nuyts, I. Vreys, H. Deckmyn, and J. Vermynen. 1997. von Willebrand factor binds to native collagen VI primarily via its A1 domain. *The Biochemical journal* 324 (Pt 1):185-91.
 29. Lankhof, H., M. van Hoeij, M. E. Schiphorst, M. Bracke, Y. P. Wu, M. J. Ijsseldijk, T. Vink, P. G. de Groot, and J. J. Sixma. 1996. A3 domain is essential for interaction of von Willebrand factor with collagen type III. *Thrombosis and haemostasis* 75:950-8.
 30. Alevriadou, B. R., J. L. Moake, N. A. Turner, Z. M. Ruggeri, B. J. Folie, M. D. Phillips, A. B. Schreiber, M. E. Hrinda, and L. V. McIntire. 1993. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. *Blood* 81:1263-76.
 31. Farndale, R. W., J. J. Sixma, M. J. Barnes, and P. G. de Groot. 2004. The role of collagen in thrombosis and hemostasis. *J Thromb Haemost* 2:561-73.
 32. Barnes, M. J., and R. W. Farndale. 1999. Collagens and atherosclerosis. *Experimental gerontology* 34:513-25.
 33. Saelman, E. U., H. K. Nieuwenhuis, K. M. Hese, P. G. de Groot, H. F. Heijnen, E. H. Sage, S. Williams, L. McKeown, H. R. Gralnick, and J. J. Sixma. 1994. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). *Blood* 83:1244-50.
 34. Knight, C. G., L. F. Morton, D. J. Onley, A. R. Peachey, T. Ichinohe, M. Okuma, R. W. Farndale, and M. J. Barnes. 1999. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. *Cardiovascular research* 41:450-7.
 35. Ruan, C., G. Tobelem, A. J. McMichael, L. Drouet, Y. Legrand, L. Degos, N. Kieffer, H. Lee, and J. P. Caen. 1981. Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. *British journal of haematology* 49:511-9.
 36. Coller, B. S., E. I. Peerschke, L. E. Scudder, and C. A. Sullivan. 1983. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. *Blood* 61:99-110.
 37. Fox, J. E., L. P. Aggerbeck, and M. C. Berndt. 1988. Structure of the glycoprotein Ib.IX complex from platelet membranes. *The Journal of biological chemistry* 263:4882-90.
 38. Shen, Y., G. M. Romo, J. F. Dong, A. Schade, L. V. McIntire, D. Kenny, J. C. Whisstock, M. C. Berndt, J. A. Lopez, and R. K. Andrews. 2000. Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. *Blood* 95:903-10.
 39. Savage, B., E. Saldivar, and Z. M. Ruggeri. 1996. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell* 84:289-97.
 40. Sixma, J. J., G. H. van Zanten, E. G. Huizinga, R. M. van der Plas, M. Verkley, Y. P. Wu, P. Gros, and P. G. de Groot. 1997. Platelet adhesion to collagen: an update. *Thrombosis and haemostasis* 78:434-8.
 41. Ruggeri, Z. M. 1997. Mechanisms initiating platelet thrombus formation. *Thrombosis and haemostasis* 78:611-6.
 42. Asazuma, N., Y. Ozaki, K. Satoh, Y. Yatomi, M. Handa, Y. Fujimura, S. Miura, and S. Kume. 1997. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. *Blood* 90:4789-98.
 43. Kasirer-Friede, A., M. R. Cozzi, M. Mazzucato, L. De Marco, Z. M. Ruggeri, and S. J. Shattil. 2004. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. *Blood* 103:3403-11.
 44. Milner, E. P., Q. Zheng, and J. C. Kermod. 1998. Ristocetin-mediated interaction of human von Willebrand factor with platelet glycoprotein Ib evokes a transient calcium signal: observations with Fura-PE3. *The Journal of laboratory and clinical medicine* 131:49-62.
 45. Munday, A. D., M. C. Berndt, and C. A. Mitchell. 2000. Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. *Blood* 96:577-84.
 46. Nesbitt, W. S., S. Kulkarni, S. Giuliano, I. Goncalves, S. M. Dopheide, C. L. Yap, I. S. Harper, H. H. Salem, and S. P. Jackson. 2002. Distinct glycoprotein Ib/V/

- IX and integrin alpha IIb beta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow. *The Journal of biological chemistry* 277:2965-72.
47. Yuan, Y., S. Kulkarni, P. Ulsemer, S. L. Cranmer, C. L. Yap, W. S. Nesbitt, I. Harper, N. Mistry, S. M. Dopheide, S. C. Hughan, D. Williamson, C. de la Salle, H. H. Salem, F. Lanza, and S. P. Jackson. 1999. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. *The Journal of biological chemistry* 274:36241-51.
 48. Kunicki, T. J., D. J. Nugent, S. J. Staats, R. P. Orzechowski, E. A. Wayner, and W. G. Carter. 1988. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. *The Journal of biological chemistry* 263:4516-9.
 49. Nieuwenhuis, H. K., J. W. Akkerman, W. P. Houdijk, and J. J. Sixma. 1985. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. *Nature* 318:470-2.
 50. Santoro, S. A. 1986. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. *Cell* 46:913-20.
 51. Sixma, J. J., G. H. van Zanten, E. U. Saelman, M. Verkleij, H. Lankhof, H. K. Nieuwenhuis, and P. G. de Groot. 1995. Platelet adhesion to collagen. *Thrombosis and haemostasis* 74:454-9.
 52. Santoro, S. A., J. J. Walsh, W. D. Staatz, and K. J. Baranski. 1991. Distinct determinants on collagen support alpha 2 beta 1 integrin-mediated platelet adhesion and platelet activation. *Cell regulation* 2:905-13.
 53. Jung, S. M., and M. Moroi. 1998. Platelets interact with soluble and insoluble collagens through characteristically different reactions. *The Journal of biological chemistry* 273:14827-37.
 54. Jung, S. M., and M. Moroi. 2000. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1). *The Journal of biological chemistry* 275:8016-26.
 55. Siljander, P. R., I. C. Munnix, P. A. Smethurst, H. Deckmyn, T. Lindhout, W. H. Ouwehand, R. W. Farndale, and J. W. Heemskerk. 2004. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. *Blood* 103:1333-41.
 56. Moroi, M., I. Onitsuka, T. Imaizumi, and S. M. Jung. 2000. Involvement of activated integrin alpha2beta1 in the firm adhesion of platelets onto a surface of immobilized collagen under flow conditions. *Thrombosis and haemostasis* 83:769-76.
 57. Clemetson, J. M., J. Polgar, E. Magnenat, T. N. Wells, and K. J. Clemetson. 1999. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to Fc alpha R and the natural killer receptors. *The Journal of biological chemistry* 274:29019-29024.
 58. Jandrot-Perrus, M., S. Busfield, A. H. Lagrue, X. Xiong, N. Debili, T. Chickering, J. P. Le Couedic, A. Goodearl, B. Dussault, C. Fraser, W. Vainchenker, and J. L. Villeval. 2000. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. *Blood* 96:1798-807.
 59. Gibbins, J. M., M. Okuma, R. Farndale, M. Barnes, and S. P. Watson. 1997. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. *FEBS letters* 413:255-9.
 60. Tsuji, M., Y. Ezumi, M. Arai, and H. Takayama. 1997. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. *The Journal of biological chemistry* 272:23528-31.
 61. Kato, K., T. Kanaji, S. Russell, T. J. Kunicki, K. Furihata, S. Kanaji, P. Marchese, A. Reininger, Z. M. Ruggeri, and J. Ware. 2003. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. *Blood* 102:1701-7.
 62. Massberg, S., M. Gawaz, S. Gruner, V. Schulte, I. Konrad, D. Zohlnhofer, U. Heinzmann, and B. Nieswandt. 2003. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. *The Journal of experimental medicine* 197:41-49.
 63. Nieswandt, B., C. Brakebusch, W. Bergmeier, V. Schulte, D. Bouvard, R. Mokhtari-Nejad, T. Lindhout, J. W. Heemskerk, H. Zirngibl, and R. Fassler. 2001. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. *The EMBO journal* 20:2120-30.
 64. Schulte, V., T. Rabie, M. Prostredna, B. Aktas, S. Gruner, and B. Nieswandt. 2003. Targeting of

- the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. *Blood* 101:3948-52.
65. Hynes, R. O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* 69:11-25.
 66. Humphries, M. J. 1996. Integrin activation: the link between ligand binding and signal transduction. *Current opinion in cell biology* 8:632-40.
 67. Gao, J. X., J. Wilkins, and A. C. Issekutz. 1995. Migration of human polymorphonuclear leukocytes through a synovial fibroblast barrier is mediated by both beta 2 (CD11/CD18) integrins and the beta 1 (CD29) integrins VLA-5 and VLA-6. *Cellular immunology* 163:178-86.
 68. Yan, S. R., L. Fumagalli, S. Dusi, and G. Berton. 1995. Tumor necrosis factor triggers redistribution to a Triton X-100-insoluble, cytoskeletal fraction of beta 2 integrins, NADPH oxidase components, tyrosine phosphorylated proteins, and the protein tyrosine kinase p58fgr in human neutrophils adherent to fibrinogen. *Journal of leukocyte biology* 58:595-606.
 69. Werb, Z., P. M. Tremble, O. Behrendtsen, E. Crowley, and C. H. Damsky. 1989. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. *The Journal of cell biology* 109:877-89.
 70. Miyake, S., H. Yagita, T. Maruyama, H. Hashimoto, N. Miyasaka, and K. Okumura. 1993. Beta 1 integrin-mediated interaction with extracellular matrix proteins regulates cytokine gene expression in synovial fluid cells of rheumatoid arthritis patients. *The Journal of experimental medicine* 177:863-8.
 71. Nathan, C. F. 1987. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. *The Journal of clinical investigation* 80:1550-60.
 72. Jennings, L. K., and D. R. Phillips. 1982. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. *The Journal of biological chemistry* 257:10458-66.
 73. Wagner, C. L., M. A. Mascelli, D. S. Neblock, H. F. Weisman, B. S. Collier, and R. E. Jordan. 1996. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. *Blood* 88:907-14.
 74. Cattaneo, M. 2003. Inherited platelet-based bleeding disorders. *J Thromb Haemost* 1:1628-1636.
 75. Nurden, A. T., and J. P. Caen. 1974. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. *British journal of haematology* 28:253-60.
 76. Haverstick, D. M., J. F. Cowan, K. M. Yamada, and S. A. Santoro. 1985. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. *Blood* 66:946-52.
 77. Plow, E. F., M. D. Pierschbacher, E. Ruoslahti, G. A. Marguerie, and M. H. Ginsberg. 1985. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. *Proceedings of the National Academy of Sciences of the United States of America* 82:8057-61.
 78. Shattil, S. J., H. Kashiwagi, and N. Pampori. 1998. Integrin signaling: the platelet paradigm. *Blood* 91:2645-57.
 79. Payrastra, B., K. Missy, C. Trumel, S. Bodin, M. Plantavid, and H. Chap. 2000. The integrin alpha IIb/beta 3 in human platelet signal transduction. *Biochemical pharmacology* 60:1069-74.
 80. Quinton, T. M., S. Murugappan, S. Kim, J. Jin, and S. P. Kunapuli. 2004. Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. *J Thromb Haemost* 2:978-84.
 81. Ruggeri, Z. M. 2002. Platelets in atherothrombosis. *Nature medicine* 8:1227-34.
 82. Abrams, C., Y. J. Deng, B. Steiner, T. O'Toole, and S. J. Shattil. 1994. Determinants of specificity of a baculovirus-expressed antibody Fab fragment that binds selectively to the activated form of integrin alpha IIb beta 3. *The Journal of biological chemistry* 269:18781-8.
 83. Shimaoka, M., J. Takagi, and T. A. Springer. 2002. Conformational regulation of integrin structure and function. *Annual review of biophysics and biomolecular structure* 31:485-516.
 84. Vinogradova, O., T. Haas, E. F. Plow, and J. Qin. 2000. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. *Proceedings of the National Academy of Sciences of the United States of America* 97:1450-5.
 85. Ma, Y. Q., J. Qin, and E. F. Plow. 2007. Platelet integrin alpha(IIb)beta(3): activation mechanisms. *J Thromb Haemost* 5:1345-52.
 86. Hughes, P. E., T. E. O'Toole, J. Ylanne, S. J. Shattil, and M. H. Ginsberg. 1995. The conserved membrane-proximal region of an integrin cytoplasmic domain specifies ligand binding affinity. *The Journal of*

Hosseini et al.

- biological chemistry 270:12411-7.
87. Loh, E., W. Qi, G. Vilaire, and J. S. Bennett. 1996. Effect of cytoplasmic domain mutations on the agonist-stimulated ligand binding activity of the platelet integrin α IIb β 3. *The Journal of biological chemistry* 271:30233-41.
 88. Ruiz, C., C. Y. Liu, Q. H. Sun, M. Sigaud-Fiks, E. Fressinaud, J. Y. Muller, P. Nurden, A. T. Nurden, P. J. Newman, and N. Valentin. 2001. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (α IIb β 3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. *Blood* 98:2432-41.
 89. Wang, R., S. J. Shattil, D. R. Ambruso, and P. J. Newman. 1997. Truncation of the cytoplasmic domain of β 3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin α (IIb) β 3 complex. *The Journal of clinical investigation* 100:2393-403.
 90. Lindbom, L., and J. Werr. 2002. Integrin-dependent neutrophil migration in extravascular tissue. *Seminars in immunology* 14:115-21.
 91. Kulkarni, S., S. M. Dopheide, C. L. Yap, C. Ravanat, M. Freund, P. Mangin, K. A. Heel, A. Street, I. S. Harper, F. Lanza, and S. P. Jackson. 2000. A revised model of platelet aggregation. *The Journal of clinical investigation* 105:783-91.
 92. Ruggeri, Z. M. 1997. von Willebrand factor. *The Journal of clinical investigation* 100:S41-6.
 93. Kulkarni, S., and S. P. Jackson. 2004. Platelet factor XIII and calpain negatively regulate integrin α IIb β 3 adhesive function and thrombus growth. *The Journal of biological chemistry* 279:30697-706.